Andere Sprachen Celltrion, Inc.

Aktien

A068270

KR7068270008

A068270

Biotechnologie

Schlusskurs Korea S.E. Andere Börsenplätze 16.06.2025			% 5 Tage	% 1. Jan.
161.800,00 ^KRW	+0,62 %		+3,17 %	-10,25 %

27.05.	Südkoreanische Aktien geben aufgrund von Gewinnmitnahmen nach; Korea Zinc verliert 4 % aufgrund einer Untersuchung durch die KFTC	MT
27.05.	Celltrion gibt angesichts von Bedenken hinsichtlich der Bewertung fast 8,5 Millionen Bonusaktien aus	MT

Andere Sprachen

Celltrion : announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients	16.06.
South Korean Shares Slip on Profit-Booking; Korea Zinc Loses 4% on KFTC Probe	27.05.
Celltrion to Issue Nearly 8.5 Million Bonus Shares Amid Valuation Concerns	27.05.
Celltrion Inc To Issue 8.5 Million Bonus Shares	26.05.
US FDA Expands Interchangeable Status for Celltrion's Humira Biosimilar Yuflyma	22.05.
Celltrion's YUFLYMA® (Alalimumab-Aaty) Receives FDA Interchangeability Designation for All Its Approved Doseforms and Strengthens	22.05.
S.Korean shares end higher as pharma stocks jump on government's support pledge	21.05.
South Korea vows more policy support, including for drugmakers, as US tariffs weigh	21.05.
South Korean shares rise 1% as pharmaceutical stocks jump	21.05.
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 3, 2025.	20.05.
Celltrion, Inc. announces an Equity Buyback for 649,351 shares.	20.05.
Celltrion, Inc. authorizes a Buyback Plan.	20.05.
Celltrion Inc To Buy Back 100 Billion Won Worth Shares	20.05.
Celltrion Chairman Says US Drug Price Reform Unlikely to Impact Business	16.05.
Celltrion, Inc.'s Equity Buyback announced on April 3, 2025, has closed with 631,712 shares, representing 0.29% for KRW 99,566.21 million.	16.05.
Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	15.05.
Hyundai ADM Bio Voluntary Withdraws IND for Clinical Study of Docetaxel Combination Cancer Therapy to Focus on Immunotherapy Strategy	13.05.
South Korean shares gain over 1% on US-China trade optimism	12.05.
Celltrion : Investor Presentation May & June 2025	12.05.
Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs	12.05.
Celltrion To Cancel Its Own Shares Worth 98.5 Billion Won	12.05.
Celltrion Adalimumab Biosimilar Granted Interchangeability Designation	29.04.
Celltrion, Inc. to Present Six Abstracts in Inflammative Disease Week at 2025 Digestive Disease Week®?	28.04.
Celltrion, Inc. announces an Equity Buyback for 631,712 shares.	28.04.
Celltrion, Inc. authorizes a Buyback Plan.	28.04.

Keine Ergebnisse zu dieser Suche

Mehr Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Celltrion, Inc.

Aktien

A068270

KR7068270008

A068270

Biotechnologie

Andere Sprachen

Filter